As previously reported, BofA initiated coverage of iRhythm (IRTC) with a Buy rating and $200 price target The Zio wireless patch-based sensor is “best in class” for long term continuous monitoring of electrocardiogram data to diagnose arrhythmias, the analyst tells investors. The firm, which sees share gain potential in the mobile cardiac telemetry segment of the market, also notes that the company is driving market expansion with primary care physicians and asymptomatic patients and is at a turning point in EBITDA profitability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm initiated with a Buy at BofA
- Dayforce said in talks to be acquired, Soho House to go private: Morning Buzz
- Spruce Point says it’s short iRhythm, sees 40%-70% potential LT downside
- iRhythm announces publication of AVALON study of Zio LTCM
- iRhythm price target raised to $175 from $160 at Truist